A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction

References

• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228. doi:10.1016/j.jacc.2014.09.017
   PubMed Web of Science ®Google Scholar
• Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41(1):12–85. doi:10.1093/eurheartj/ehz859
   PubMed Web of Science ®Google Scholar
• Lenzen MJ, Boersma E, Bertrand ME, et al. Management and outcome of patients with established coronary artery disease: the Euro heart survey on coronary revascularization. Eur Heart J. 2005;26(12):1169–1179. doi:10.1093/eurheartj/ehi238
   PubMed Web of Science ®Google Scholar
• Bouisset F, Ruidavets JB, Dallongeville J, et al. Comparison of short- and long-term prognosis between ST-Elevation and Non-ST-elevation myocardial infarction. J Clin Med. 2021;10:2. doi:10.3390/jcm10020180
   Web of Science ®Google Scholar
• Eagle KA, Ginsburg GS, Musunuru K, et al. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation. 2010;121(12):1447–1454. doi:10.1161/CIRCULATIONAHA.109.904029
   Web of Science ®Google Scholar
• Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–842. doi:10.1001/jama.284.7.835
   PubMed Web of Science ®Google Scholar
• Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001;358(9293):1571–1575. doi:10.1016/S0140-6736(01)06649-1
   PubMed Web of Science ®Google Scholar
• Bawamia B, Mehran R, Qiu W, Kunadian V. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am Heart J. 2013;165(4):441–450. doi:10.1016/j.ahj.2012.12.020
   Web of Science ®Google Scholar
• Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. doi:10.1136/bmj.38985.646481.55
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–2733. doi:10.1001/jama.291.22.2727
   PubMed Web of Science ®Google Scholar
• Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol. 2010;55(14):1403–1415. doi:10.1016/j.jacc.2009.09.071
   Web of Science ®Google Scholar
• Widera C, Pencina MJ, Meisner A, et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J. 2012;33(9):1095–1104. doi:10.1093/eurheartj/ehr444
   PubMed Web of Science ®Google Scholar
• Lindholm D, James SK, Gabrysch K, et al. Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol. 2018;3(12):1160–1166. doi:10.1001/jamacardio.2018.3811
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–172;discussion 207–112. doi:10.1002/sim.2929
   PubMed Web of Science ®Google Scholar
• Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–2353. doi:10.1001/archinte.163.19.2345
   PubMedGoogle Scholar
• Tang EW, Wong CK, Herbison P. Global registry of acute coronary events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J. 2007;153(1):29–35. doi:10.1016/j.ahj.2006.10.004
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Spencer FA, Yarzebski J, et al. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the worcester heart attack study). Am J Cardiol. 2004;94(11):1373–1378. doi:10.1016/j.amjcard.2004.07.142
   Web of Science ®Google Scholar
• Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA. 2007;297(17):1892–1900. doi:10.1001/jama.297.17.1892
   PubMed Web of Science ®Google Scholar
• Kühl JT, Møller JE, Kristensen TS, Kelbæk H, Kofoed KF. Left atrial function and mortality in patients with NSTEMI an MDCT study. JACC Cardiovasc Imaging. 2011;4(10):1080–1087. doi:10.1016/j.jcmg.2011.08.008
   Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105(15):1760–1763. doi:10.1161/01.CIR.0000015464.18023.0A
   PubMed Web of Science ®Google Scholar
• Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation. 2017;136(12):1155–1166. doi:10.1161/CIRCULATIONAHA.117.029870
   PubMed Web of Science ®Google Scholar
• de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders. Semin Thromb Hemost. 2009;35(4):356–366. doi:10.1055/s-0029-1225758
   PubMed Web of Science ®Google Scholar
• Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003;29(5):435–450.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011;25(6):239–245. doi:10.1016/j.blre.2011.05.001
   Web of Science ®Google Scholar
• Shi Y, Wu Y, Bian C, Zhang W, Yang J, Xu G. Predictive value of plasma fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010;37(2):178–183.
   PubMed Web of Science ®Google Scholar
• Karahan O, Acet H, Ertaş F, et al. The relationship between fibrinogen to albumin ratio and severity of coronary artery disease in patients with STEMI. Am J Emerg Med. 2016;34(6):1037–1042. doi:10.1016/j.ajem.2016.03.003
   PubMed Web of Science ®Google Scholar
• He D, Jiao Y, Yu T, et al. Prognostic value of fibrinogen-to-albumin ratio in predicting 1-year clinical progression in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med. 2019;18(4):2972–2978. doi:10.3892/etm.2019.7890
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu C, Liu J, et al. Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study. Cardiovasc Diabetol. 2019;18(1):52. doi:10.1186/s12933-019-0858-5
   PubMed Web of Science ®Google Scholar
• Galla JM, Mahaffey KW, Sapp SK, et al. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006;151(1):16–24. doi:10.1016/j.ahj.2005.01.045
   Web of Science ®Google Scholar
• Jernberg T, Lindahl B, James S, Ronquist G, Wallentin L. Comparison between strategies using creatine kinase-MB(mass), myoglobin, and troponin T in the early detection or exclusion of acute myocardial infarction in patients with chest pain and a nondiagnostic electrocardiogram. Am J Cardiol. 2000;86(12):1367–1371, a1365. doi:10.1016/S0002-9149(00)01245-5
   Web of Science ®Google Scholar
• Chin CT, Wang TY, Li S, et al. Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the acute coronary treatment and intervention outcomes network registry-get with the guidelines. Clin Cardiol. 2012;35(7):424–429. doi:10.1002/clc.21980
   Web of Science ®Google Scholar
• Hedges JR. The role of CK-MB in chest pain decision-making. J Accid Emerg Med. 1995;12(2):101–106. doi:10.1136/emj.12.2.101
   Google Scholar
• Bostan MM, Stătescu C, Anghel L, Șerban IL, Cojocaru E, Sascău R. Post-myocardial infarction ventricular remodeling biomarkers-the key link between pathophysiology and clinic. Biomolecules. 2020;10:11. doi:10.3390/biom10111587
   Web of Science ®Google Scholar
• Sumien N, Shetty RA, Gonzales EB. Creatine, creatine kinase, and aging. Subcell Biochem. 2018;90:145–168.
   PubMedGoogle Scholar
• Le RD, Kosowsky JM, Landman AB, Bixho I, Melanson SE, Tanasijevic MJ. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015;33(1):72–75. doi:10.1016/j.ajem.2014.10.017
   Web of Science ®Google Scholar
• Wiens EJ, Arbour J, Thompson K, Seifer CM. Routine creatine kinase testing does not provide clinical utility in the emergency department for diagnosis of acute coronary syndromes. BMC Emerg Med. 2019;19(1):37. doi:10.1186/s12873-019-0251-4
   Web of Science ®Google Scholar
• Halkin A, Stone GW, Grines CL, et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2006;47(5):951–961. doi:10.1016/j.jacc.2005.12.003
   Web of Science ®Google Scholar
• Nienhuis MB, Ottervanger JP, de Boer M-J, et al. Prognostic importance of creatine kinase and creatine kinase–MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J. 2008;155(4):673–679. doi:10.1016/j.ahj.2007.11.004
   Web of Science ®Google Scholar
• Jernberg T, James S, Lindahl B, Stridsberg M, Venge P, Wallentin L. NT-ProBNP in non–ST-elevation acute coronary syndrome. J Card Fail. 2005;11(5):S54–S58. doi:10.1016/j.cardfail.2005.04.010
   Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–163. doi:10.1016/j.cca.2018.05.046
   PubMed Web of Science ®Google Scholar
• Hahn K, Kanbay M, Lanaspa MA, Johnson RJ, Ejaz AA. Serum uric acid and acute kidney injury: a mini review. J Adv Res. 2017;8(5):529–536. doi:10.1016/j.jare.2016.09.006
   PubMed Web of Science ®Google Scholar
• Magnoni M, Berteotti M, Ceriotti F, et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017;240:25–29. doi:10.1016/j.ijcard.2017.04.027
   PubMed Web of Science ®Google Scholar
• Cicero AF, Rosticci M, Cagnati M, et al. Serum uric acid and markers of low-density lipoprotein oxidation in nonsmoking healthy subjects: data from the brisighella heart study. Pol Arch Med Wewn. 2014;124(12):661–668. doi:10.20452/pamw.2548
   Web of Science ®Google Scholar
• Trkulja V, Car S. On-admission serum uric acid predicts outcomes after acute myocardial infarction: systematic review and meta-analysis of prognostic studies. Croat Med J. 2012;53(2):162–172. doi:10.3325/cmj.2012.53.162
   PubMed Web of Science ®Google Scholar
• Yan L, Liu Z, Zhang C. Uric acid as a predictor of in-hospital mortality in acute myocardial infarction: a meta-analysis. Cell Biochem Biophys. 2014;70(3):1597–1601. doi:10.1007/s12013-014-0101-7
   Web of Science ®Google Scholar
• Li L, Zhao M, Wang C, et al. Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. Clin Res Cardiol. 2021;110(7):1096–1105. doi:10.1007/s00392-021-01849-4
   PubMed Web of Science ®Google Scholar
• Claessen BE, Guedeney P, Gibson CM, et al. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc. 2020;9(24):e018897. doi:10.1161/JAHA.120.018897
   Web of Science ®Google Scholar
• Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557–1567. doi:10.1056/NEJMra1806939
   PubMed Web of Science ®Google Scholar
• Wang HH, Garruti G, Liu M, Portincasa P, Wang DQ. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann Hepatol. 2017;16(1):s27–s42. doi:10.5604/01.3001.0010.5495
   Web of Science ®Google Scholar
• Libby P, Bornfeldt KE, Tall AR. Atherosclerosis: successes, surprises, and future challenges. Circ Res. 2016;118(4):531–534. doi:10.1161/CIRCRESAHA.116.308334
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–1492. doi:10.1161/CIRCULATIONAHA.118.037184
   PubMed Web of Science ®Google Scholar
• Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 2015;52(2):70–85. doi:10.3109/10408363.2014.992063
   PubMed Web of Science ®Google Scholar
• Faber J, Hvas AM, Kristensen SD, et al. Immature platelets and risk of cardiovascular events among patients with ischemic heart disease: a systematic review. Thromb Haemost. 2021;121(5):659–675. doi:10.1055/s-0040-1721386
   PubMed Web of Science ®Google Scholar